VOGRIG, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 1.060
EU - Europa 545
AS - Asia 294
AF - Africa 26
OC - Oceania 2
SA - Sud America 1
Totale 1.928
Nazione #
US - Stati Uniti d'America 1.049
IT - Italia 272
SG - Singapore 143
IE - Irlanda 70
RU - Federazione Russa 62
CN - Cina 57
DE - Germania 41
IN - India 34
UA - Ucraina 27
FI - Finlandia 24
TG - Togo 23
VN - Vietnam 18
TR - Turchia 12
HK - Hong Kong 10
SE - Svezia 10
CA - Canada 9
GB - Regno Unito 9
BE - Belgio 6
NL - Olanda 6
JP - Giappone 5
CZ - Repubblica Ceca 4
PT - Portogallo 4
FR - Francia 3
TW - Taiwan 3
AU - Australia 2
CU - Cuba 2
ES - Italia 2
ID - Indonesia 2
KR - Corea 2
LT - Lituania 2
PH - Filippine 2
PL - Polonia 2
SA - Arabia Saudita 2
AT - Austria 1
CL - Cile 1
EG - Egitto 1
IR - Iran 1
KE - Kenya 1
KZ - Kazakistan 1
MY - Malesia 1
SC - Seychelles 1
TH - Thailandia 1
Totale 1.928
Città #
Fairfield 136
Singapore 122
Boardman 104
Chandler 75
Ashburn 73
Trieste 71
Dublin 70
Woodbridge 63
Seattle 54
Houston 49
Wilmington 45
Cambridge 41
Ogden 29
Milan 26
Venezia 24
Lomé 23
Dearborn 22
Princeton 20
Ann Arbor 19
Hyderabad 19
Dong Ket 17
Munich 17
Udine 17
Tavagnacco 16
Beijing 12
Jacksonville 12
Lappeenranta 12
Redmond 12
Helsinki 11
Hong Kong 9
Izmir 8
San Diego 8
Frankfurt am Main 7
Bologna 6
Brussels 6
Norwalk 6
Santa Clara 6
Codroipo 5
Guangzhou 5
New Delhi 5
Nove 5
Toronto 5
Amsterdam 4
Beppu 4
Lisbon 4
London 4
Los Angeles 4
Zhengzhou 4
Bolzano 3
Brno 3
Buffalo 3
Cedar Knolls 3
Chicago 3
Des Moines 3
Phoenix 3
Pune 3
Rochester 3
Rome 3
Salt Lake City 3
Shanghai 3
Ankara 2
Augusta 2
Chions 2
Dallas 2
Desio 2
Fayetteville 2
Gdynia 2
Havana 2
Hillsboro 2
Istanbul 2
Kunming 2
Leawood 2
Mableton 2
Modena 2
New York 2
Novate Milanese 2
Ortona 2
Pamplona 2
Porcia 2
Riyadh 2
Saint Paul 2
Seoul 2
Silea 2
Trento 2
Treviso 2
Turin 2
Venice 2
Verona 2
Wuhan 2
Xi'an 2
Andover 1
Ardabil 1
Baoding 1
Brescia 1
Cairo 1
Camponogara 1
Chennai 1
Columbia 1
Florence 1
Garbagnate Milanese 1
Totale 1.422
Nome #
Epidemiology of autoimmune versus infectious encephalitis 129
Tacrolimus-induced severe headache associated with diffuse leukoencephalopathy: Evidence for an immune-mediated pathogenesis 114
Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis 110
Effect of thymectomy on refractory autoimmune status epilepticus 105
Epidemiology of paraneoplastic neurological syndromes: a population-based study 89
Seizure specificities in patients with antibody-mediated autoimmune encephalitis 85
Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario 77
Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature 70
Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features 69
Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up 45
Reply to "Guillain‑Barré syndrome in the COVID‑19 era another occasional cluster?": Insights from two distinct clusters of Guillain–Barré syndrome detected in Europe in the COVID-19 era 41
Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination 41
HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome 39
Response to Letter to the Editor on the article “Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination” 36
Causality in COVID-19-associated stroke: a uniform case definition for use in clinical research 35
Stroke in patients with SARS-CoV-2 infection: case series 34
Reader Response: Prolonged Unconsciousness Following Severe COVID-19 30
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review 29
Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series 27
Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA) 27
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 26
Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination 25
Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features 24
Unclear association between COVID-19 and Guillain-Barré syndrome 23
Movement disorders in oncology: From clinical features to biomarkers 22
Stroke in patients with COVID-19: Clinical and neuroimaging characteristics 21
Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases 21
Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review 20
Back to the future: encephalitis lethargica as an autoimmune disorder? 20
Bilateral carotid artery dissection in a SARS-CoV-2 infected patient: causality or coincidence? 19
Paraneoplastic encephalitis: clinically based approach on diagnosis and management 19
Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome 18
Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience 18
Seizures, Epilepsy, and NORSE Secondary to Autoimmune Encephalitis: A Practical Guide for Clinicians 17
Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses 17
Central nervous system adverse events of immune checkpoint inhibitors 17
Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study 17
How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update 16
Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis 16
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features 15
Diagnosis of autoimmune encephalitides: An update 15
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors 15
Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study 15
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors 14
Associations between HLA and autoimmune neurological diseases with autoantibodies 14
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis 14
Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis 14
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 14
Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment 14
Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis 13
Glioblastoma as differential diagnosis of autoimmune encephalitis 13
Immunomodulation in the acute phase of autoimmune encephalitis 13
Role of LGI1 protein in synaptic transmission: From physiology to pathology 13
18F-FDG PET brain findings in disease-discordant monozygotic mosaic twins with Cri du Chat (5p-) syndrome 13
Proceedings of the “International Congress on Structural Epilepsy & Symptomatic Seizures” (STESS, Gothenburg, Sweden, 29–31 March 2023) 13
Adenovirus COVID-19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis 13
Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma 13
Intra-carotid self-injection of alprazolam: an unusual cause of unilateral multiembolic stroke 13
A systematic study of stereotypy in epileptic seizures versus psychogenic seizure-like events 13
Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis 13
Bornavirus associated with fatal human encephalitis 12
Central nervous system complications associated with immune checkpoint inhibitors 12
Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition 12
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity 11
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis 11
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies 11
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors 11
Epileptic phenotypes in autoimmune encephalitis: From acute symptomatic seizures to autoimmune-associated epilepsy 11
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France 11
Editorial: Neuroglial antibodies: From clinical associations to pathophysiological investigations 10
Prognosis of status epilepticus in adults: recent advances and future directions 10
Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors 10
Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies 10
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes 10
SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients 10
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis: Clues for Diagnosis 10
SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques 10
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes 10
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes 10
NRAS Q61K mutated diffuse leptomeningeal melanomatosis in an adult patient with a brief review of the so-called “forme fruste” of neurocutaneous melanosis 10
Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review 10
Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies 10
Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis 9
Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis 9
Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies 9
Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities 9
Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review 9
Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis 9
Post-acute anti-NMDAR encephalitis mirrors schizophrenia 9
Neuroimmune disorders in COVID-19 9
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies 8
Nystagmus and lower extremity hyperalgesia after colectomy 8
Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromes 8
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis 7
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration 7
Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: Clues of a temporal plus network 6
Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case 6
Postencephalitic epilepsy in children and adults: Etiology matters 6
Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study 6
Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma 5
Totale 2.266
Categoria #
all - tutte 18.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.791


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020223 0 0 0 0 0 46 49 38 39 31 8 12
2020/2021255 8 22 11 20 12 24 17 23 46 14 25 33
2021/2022183 9 18 37 6 2 0 13 4 3 20 48 23
2022/2023528 20 18 3 19 176 179 4 8 31 6 17 47
2023/2024343 28 22 5 24 40 18 9 31 44 57 29 36
2024/2025535 85 140 93 70 71 76 0 0 0 0 0 0
Totale 2.275